BioSpace News Archive

Rising incidents of sports injuries and increasing number of arthroscopic surgeries being performed are some key factors driving market revenue growth.

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the U.S. Food and Drug Administration (FDA) has awarded their EV drug product ExoFlo with a Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.

The industry analysis report is considered a valuable source of information about the global Homogenizers industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years

The U.S. Food and Drug Administration and the U.S. Drug Enforcement Administration recently issued joint warning letters to operators of two websites illegally selling Schedule II stimulants, including amphetamine drug products marketed as Adderall.

Apotex Corp. announced today its release of Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxane® in the United States.

Increasing prevalence of chronic diseases, rising number of surgical procedures, and growing preference for minimally invasive surgeries are some key factors expected to drive global market growth.

Gain Therapeutics, Inc., a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, presented new pre-clinical data from its Parkinson’s Disease program.

The Barbara Ann Karmanos Cancer Institute, headquartered in Detroit, has completed its expansion into Ohio with the opening of the Karmanos Cancer Institute at The Toledo Clinic Cancer Center in Maumee.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced it proposes to elect Maria Fardis, Ph.D., MBA, to its Board of Directors at the Company’s upcoming annual general of shareholders meeting to be held later this year.

Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, announced that Katherine L. Ruffner, M.D., chief medical officer, will be leaving the Company on April 22, 2022, to pursue a new opportunity.